Ijeoma Agbara
NPI 1912372343 · Pharmacist · Baltimore, MD
Provider details
- NPI number
- 1912372343
- Entity type
- Individual
- Primary specialty
- PharmacistPharmacy Service Providers
- Sex
- Female
- Sole proprietor
- No
- License
- 23646 (MD)
Specialties & taxonomies
Pharmacy Service Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure38% of score
10 yrs in NPPES registry
- Profile completeness38% of score
100% of core fields populated
- Practice footprint23% of score
1 documented practice location
Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our methodology.
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 3 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Rsvpref3 Antigen/As01e/Pfbrand: Arexvy | 36 | 36 |
| Diphth,pertuss(acell),tet Vacbrand: Boostrix Tdap | 26 | 26 |
| Varicella-Zoster Ge/As01b/Pfbrand: Shingrix | 17 | 15 |
Medicare Part D only. These counts cover prescriptions paid through Medicare Part D in 2024 — they do notinclude cash-pay, commercial-insurance, Medicaid, or Part B–administered drugs, and badly undercount high cash-pay categories (e.g. GLP-1 weight-loss, testosterone, and ED medications). Any drug with 10 or fewer claims is omitted by CMS, and beneficiary counts under 11 are suppressed — so a missing drug means no Part D record, never zero. This is a factual claims summary, not an endorsement, not medical advice, and not a consumer report. Source: CMS Medicare Part D Prescribers — by Provider and Drug.
Practice location
Mailing address
Registry dates
- Enumerated
- 2015-12-10
- Last updated
- 2015-12-10
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.